Please use this identifier to cite or link to this item:
Title: Exploring survival outcomes in metastatic colorectal cancer harboring KRAS A146 mutations: Important distinction or simple distraction?
Epworth Authors: Pham, Richard
Other Authors: Jalali, Azim
Chong, Chia
Wong, Vanessa
Dunn, Kate
Gibbs, Peter
Keywords: Prognostic Association
Metastatic Colorectal Cancer
Liver Metastases
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Mar-2022
Publisher: American Society of Clinical Oncology
Citation: JCO Precis Oncol . 2022 Mar;6:e2100564
Abstract: Erve et al report an intriguing new prognostic association of KRAS-A146 mutations in metastatic colorectal cancer in their analysis of a cohort of patients with liver metastases, including 12 with the KRAS-A146 mutation. They reported a marked reduction in overall survival (median 10.7 v 26.4 months; hazard ratio = 2.5; P = .003), which was associated with an increased bulk of disease as measured by circulating tumor DNA and radiologically assessed total tumor volume. In the absence of previous reports documenting a major impact of other KRAS mutations, we further explored the impact of KRAS-A146 by analyzing data from a large multisite registry and were unable to reproduce the association reported by Erve et al.
DOI: 10.1200/PO.21.00564
PubMed URL:
ISSN: 2473-4284
Journal Title: JCO Precision Oncology
Type: Letter
Affiliated Organisations: Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research
Type of Clinical Study or Trial: N/A
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.